Member Info for RegulatorUK

"Interesting. It seems that those that wanted shares also asked for extra and did not get all the extra that they were hoping for. But nearly half (46%) didn't even apply for the basic entitlement."

I don't think that's what the sentence in the RNS means. The 54% relates to the number of shares available in the OO - not to the number of eligible investors. My reading of the initial offer was that the number of shares that were being offered exceeded the number that would allocated using the 1:20 entitlement.

Sorry - but I'm going on the peer-reviewed clinical evidence.

For an 'immunity passport' to be effective, you would have to be able to demonstrate that prior infection consistently produced long-term immunity. The evidence to date doesn't support that and suggests that any immunity is short-lived - a matter of months, rather than years or lifetime.

'Immunity Passports' are unlikely to work... as the emerging evidence is that any immunity appears is short-lived. There's no way (at present) of telling how long someone's immunity will last.

The only real way out of this will be containment, followed by widespread testing and vaccination. The latter is some time off.

What UK-RTC/ODX will be producing is a POC test. It doesn't require a lab. That's the beauty of it and why reliable POC tests are so sought after. Yes, testing for Covid19 will be with us for some time but that will increasingly be on the basis of POC rather than lab-based tests (which will be reserved primarily for those who are symptomatic and admitted to healthcare settings).

The procurement announced was in relation to lab-based testing (primarily PCR). It's being undertaken because the UK public health realm has faced severe under investment in the last 10 years or so, which meant it was ill-equipped to deal with Covid19 - and would collapse entirely if we get hit with an emergent strain like G4 (if it transfers to humans).

The procurement isn't directly relevant to UK-RTC/ODX, although it might have a knock on effect as any health related 'good news' investment story tends to have a vicarious effect.

I've invested heavily in ODX because, as part of the UK-RTC it will be producing a gold standard POC test. It's a long term keeper.

Block16legend is correct.

The notice relates to the Lighthouse labs and the testing kits/equipment to support those. It’s about PCR testing - not POC ELISA testing.

Arden & GEM is not a PCT. PCTs were abolished in 2013. It’s not a trust either. It’s a CSU. It would not buy 3,500 desktops for diagnostics - that would be handled by another NHS organisation.